drugset / Trial / NCT05548296
A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This is an open label Phase 2 study to evaluate the efficacy and safety of ACR-368 as monotherapy or with ultra-low dose gemcitabine (ULDG) sensitization in participants with endometrial cancer.
Timeline
- Start
- 2022-08-29
- Primary completion
- 2027-05-30
- Completion
- 2027-11-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Gemcitabine | Small molecule | — | — |
| Subject | Prexasertib | Small molecule | — | — |